STAT

Opinion: Peer review could have helped short-circuit the Theranos fake news scandal

Thanks to Theranos, startups might now face a greater burden of proof to demonstrate their technology is effective.
Source: Kristoffer Tripplaar/AP

Theranos had a product almost everyone could get behind: a revolutionary blood test that would allow individuals to quickly and easily access information about their health. Startups like Theranos rely on cutting-edge innovation, then leverage that innovation to attract investors. Now the company’s downfall is a signal to innovators, the public, and the media that we need more transparency and credibility built on peer-reviewed publications.

Holmes, who was accused of falsely claiming that Theranos had developed a portable analyzer that could perform virtually any medical test using with the Security and Exchange Commission for a penalty of $500,000, among other things.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT1 min read
STAT+: Nuclear Regulatory Commission Advisers Beset By Conflicts Of Interest, Report Finds
Advisers to the Nuclear Regulatory Commission, a U.S. government agency tasked with ensuring the safe use of radioactive materials, were beset by conflicts of interest, report finds

Related Books & Audiobooks